ALKS Alkermes
- 24.130
- -0.250-1.03%
Alkermes News
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), MacroGenics (MGNX) and Alkermes (ALKS)
Alkermes Highlights Data Presentations Related to Its Psychiatry Franchise at Spring 2024 Scientific Conferences
̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for People Living with Schizophrenia or Bipolar I Disorder ̶DUB
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
7 Analysts Assess Alkermes: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview of recent rat
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Alkermes (ALKS.US) rating was reaffirmed and adjusted from neutral to neutral, with a target price of $35.00.
HC Wainwright & Co. : The Alkermes (ALKS.US) rating was reaffirmed and adjusted from neutral to neutral, with a target price of $35.00.
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 45.77% HC Wainwright & Co. → $35 Reiterates Neutral → Neutral 04/19/2024 45.77% HC Wainwright &
UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating
Alkermes (ALKS) has an average outperform rating and price target range of $21 to $50, according to analysts polled by Capital IQ. Price: 23.63, Change: -0.38, Percent Change: -1.58
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Press Release: Alkermes Plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN, May 2, 2024 DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Alkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline Prospects
Maintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline Prospects
Alkermes Plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connec
Earnings Call Summary | Alkermes(ALKS.US) Q1 2024 Earnings Conference
The following is a summary of the Alkermes Plc (ALKS) Q1 2024 Earnings Call Transcript:Financial Performance:Alkermes reported total revenues of $350.4 million in Q1 2024, driven by a growth of 9% in
Alkermes Plc (ALKS) Q1 2024 Earnings Call Transcript
Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View
Alkermes (ALKS) reported Q1 adjusted earnings Wednesday of $0.43 per diluted share, compared with $0.01 a year earlier. Analysts surveyed by Capital IQ expected $0.58. Revenue for the quarter ended Ma
Alkermes Plc Q1 Earnings Summary
Alkermes (ALKS.US): The 2024 Q1 financial report achieved revenue of US$350.4 million, with a previous value of US$287.6 million and an expected value of US$360.3 million; earnings per share were $0.44, previously $0.18, and an expected value of $0.58.
Alkermes (ALKS.US): The 2024 Q1 financial report achieved revenue of US$350.4 million, with a previous value of US$287.6 million and an expected value of US$360.3 million; earnings per share were $0.44, previously $0.18, and an expected value of $0.58.
Analysis
Price Target
No Data
